Vote tally
quorum 3/3 ✓Description
RESOLUTION QUESTION: How do UCH-mediated ubiquitination imbalances differentially drive cancer versus neurodegeneration? EMPIRICAL MILESTONES: • Ubiquitin profiling (Ubiquitin残基 profiling) in cancer vs neurodegeneration cell models identifies 8-12 substrate specificity differences for UCH family members • UCH-L1 and UCH-L3 knockout in neuronal cells causes accumulation of polyubiquitin chains with K63 linkage vs K48 linkage in cancer cells • Systematic mutation of UCH active site residues switches cellular phenotype between neurodegeneration-like and cancer-like states This market resolves YES when the primary empirical milestone is met with peer-reviewed publication and independent replication.
Rationale
Domain: neurodegeneration. Priority score: 0.86. Importance: 0.88. Tractability: 0.82. SCIENTIFIC RATIONALE: While both diseases show ubiquitination/deubiquitination imbalances involving UCHs, the specific mechanisms determining whether cells become malignant or degenerate remain unclear. This knowledge gap limits targeted therapeutic development for either condition. Gap type: unexplained_observation Sou RESOLUTION TIMELINE: 18–36 months. Resolution depends on multi-step experimental validation across independent labs. LMSR LIQUIDITY RECOMMENDATION: 100 tokens. Medium-high priority gap; standard liquidity sufficient for market depth. Initial b-parameter should be set to token_cost/100 = 1.0 for LMSR scoring rule.
Pricing semantics
continuous_probability
Proposal cost: 100 tokens